Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36, reflecting a +1.84% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which ...